NEW YORK ─ Boulder, Colorado-based Biodesix on Wednesday announced an agreement with HiberCell to conduct further development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic test.
As part of the agreement, Biodesix will develop a CDx test to select patients for enrollment in HiberCell’s future registrational clinical trials. In an initial program, the ELISA-based CDx will be validated in Biodesix’s New York State CLEP-approved and CLIA-accredited lab.